Biomarck Pharmaceuticals
Business Services · North Carolina, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
2530 Meridian Pkwy Ste 300, Durham, Nort...Phone Number
(919) 768-1335Website
www.biomarck.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
2
1
1
1
About Biomarck Pharmaceuticals
Biomarck Pharmaceuticals, Ltd. is a clinical stage biotechnology company focused on treating patients with inflammatory and immunological diseases, using the company's platform of patent-protected peptides that have been developed to inhibit MARCKS. As a critical component of the inflammatory process, MARCKS is responsible for neutrophil aggregation at the site of inflammation and cytokine release. Inhibiting MARCKS with the company's peptides reduces the adverse effects of inflammation, including acute respiratory distress syndrome (ARDS) and cytokine storm. Phase 2 trials have been completed with the company's lead peptide, BIO-11006, in ARDS, chronic obstructive pulmonary disease (COPD), and non-small cell lung cancer (NSCLC), supporting safety and efficacy in these three potential indications. In oncology, inhibiting MARCKS with the company's peptides blocks migration of NSCLC cells in vitro and inhibits metastasis in animal models of NSCLC.Explore more
Biomarck Pharmaceuticals Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Biomarck Pharmaceuticals your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when Biomarck Pharmaceuticals launches new products
Check if Biomarck Pharmaceuticals has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once Biomarck Pharmaceuticals has new funding data
Click to see if Biomarck Pharmaceuticals had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at Biomarck Pharmaceuticals
Check out if Biomarck Pharmaceuticals is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Biomarck Pharmaceuticals, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on Biomarck Pharmaceuticals recently announced quarterly report
Recommended Actions
Reach out to Masked Content who joined Biomarck Pharmaceuticals as Masked Content
Find more new buyers
Compare Similar Companies to Biomarck Pharmaceuticals
Compare insights from companies similar to Biomarck Pharmaceuticals, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Biomarck Pharmaceuticals is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Biomarck Pharmaceuticals is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Biomarck Pharmaceuticals.
Biomarck Pharmaceuticals financials insights
Gather financial insights about Biomarck Pharmaceuticals, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2013
Private Equity
$7M
2016
Private Equity
$6M
Biomarck Pharmaceuticals Tech Stack
A closer look at the technologies used by Biomarck Pharmaceuticals
Biomarck Pharmaceuticals News & Media
BIOMARCK Appoints Graham Lumsden as President and Chief Executive Officer - Opera News
Biomarck Pharmaceuticals, Ltd., a clinical-stage biopharmaceutical company developing anti-inflammatory and oncological therapies that target the MARCKS protein, today announced the appointment of Dr. Graham G. Lumsden as President and Chief ExecutiveResults of Biomarck Phase II Study of BIO-11006 in Patients with ARDS to be Presented at the 2021 ATS Annual Meeting
NEWTOWN, Pa.--(BUSINESS WIRE)-- #ARDS--Results of a Biomarck Phase II study of BIO-11006 in patients with ARDS will be presented at the ATS (American Thoracic Society) 2021 Annual Meeting.Biomarck’s MARCKS Inhibitors for Uveitis to be Presented at the 2021 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO)
NEWTOWN, Pa.--(BUSINESS WIRE)-- #cytokinestorm--Biomarck's MARCKS inhibitors for uveitis will be presented at the 2021 Annual Meeting of Association for Research in Vision and Ophthalmology (ARVO).Biomarck Pharmaceuticals presents at H.C. Wainwright 2021 Global Life Sciences Conference on March 9-10, 2021
NEWTOWN, Pa.--(BUSINESS WIRE)-- #cytokinestorm--Biomarck Pharmaceuticals presents at H.C. Wainwright 2021 Global Life Sciences Conference on March 9-10, 2021
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Biomarck Pharmaceuticals
Sign Up For FreeTo access detailed company insights
Biomarck Pharmaceuticals, Ltd. is a clinical stage biotechnology company focused on treating patients with inflammatory and immunological diseases, using the company's platform of patent-protected peptides that have been developed to inhibit MARCKS. As a critical component of the inflammatory process, MARCKS is responsible for neutrophil aggregatio... Read More
